Last Price$165.9(1.1%)
Market Cap$398.7B
LTM Net Debt
$12.1B
YoY Growth
+89.1%
3Y CAGR
+78.1%
5Y CAGR
+7.6%
Stock quality & Intrinsic value
6/10
18.9% undervalued
Johnson & Johnson Net Debt
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jan'06 | Dec'06 | Dec'07 | Dec'08 | Jan'10 | Jan'11 | Jan'12 | Dec'12 | Dec'13 | Dec'14 | Jan'16 | Jan'17 | Dec'17 | Dec'18 | Dec'19 | Jan'21 | Jan'22 | Jan'23 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt | ($13.5B) | $2,509.0M | $222.0M | ($957.0M) | ($4,884.0M) | ($10.9B) | ($12.6B) | ($4,924.0M) | ($11.0B) | ($14.3B) | ($18.5B) | ($14.8B) | $16.3B | $10.8B | $8,409.0M | $10.1B | $2,143.0M | $18.5B | $7,505.0M | $12.1B |
Overvalued or undervalued?
Check the intrinsic value for JNJ
and see if it's the right time to invest.
Johnson & Johnson (JNJ) Net Debt comparison analysis
General
LTM Net Debt
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Johnson & JohnsonJNJ
$12.1B
89.1%
78.1%
7.6%
Median Peer Set
$23.9B
(1.1%)
9.9%
3.5%
AbbVie Inc.ABBV
$61.6B
30.1%
(3.1%)
17.8%
Amgen Inc.AMGN
$48.1B
(11.7%)
22.9%
17.5%
Pfizer Inc.PFE
$43.2B
(23.5%)
93.8%
(0.2%)
Eli Lilly and CompanyLLY
$30.2B
35.5%
32.6%
17.7%
AstraZeneca PLCAZN
$24.5B
2.8%
(3.2%)
11.5%
Merck & Co., Inc.MRK
$23.4B
(19.5%)
(3.7%)
7.0%
Novartis AGNVS
$17.9B
44.6%
86.4%
0.0%
Gilead Sciences, Inc.GILD
$16.7B
(2.3%)
(4.8%)
N/A
Novo Nordisk A/SNVO
$10.6B
N/A
102.9%
N/A
SanofiSNY
$10.3B
(3.6%)
(6.8%)
(9.2%)
JNJ key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Dec'06 | Dec'07 | Dec'08 | Jan'10 | Jan'11 | Jan'12 | Dec'12 | Dec'13 | Dec'14 | Jan'16 | Jan'17 | Dec'17 | Dec'18 | Dec'19 | Jan'21 | Jan'22 | Jan'23 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 50,514.0 6.7% | 53,324.0 5.6% | 61,095.0 14.6% | 63,747.0 4.3% | 61,897.0 (2.9%) | 61,587.0 (0.5%) | 65,030.0 5.6% | 67,224.0 3.4% | 71,312.0 6.1% | 74,331.0 4.2% | 70,074.0 (5.7%) | 71,890.0 2.6% | 76,450.0 6.3% | 81,581.0 6.7% | 82,059.0 0.6% | 82,584.0 0.6% | 78,740.0 (4.7%) | 79,990.0 1.6% | 85,159.0 6.5% | 88,821.0 4.3% |
| Cost of Goods Sold (COGS) | 14,010.0 | 15,057.0 | 17,751.0 | 18,511.0 | 18,447.0 | 18,792.0 | 20,360.0 | 21,658.0 | 22,342.0 | 22,746.0 | 21,536.0 | 21,789.0 | 25,439.0 | 27,091.0 | 27,556.0 | 28,427.0 | 23,402.0 | 24,596.0 | 26,553.0 | 27,471.0 |
% margin | 36,504.0 72.3% | 38,267.0 71.8% | 43,344.0 70.9% | 45,236.0 71.0% | 43,450.0 70.2% | 42,795.0 69.5% | 44,670.0 68.7% | 45,566.0 67.8% | 48,970.0 68.7% | 51,585.0 69.4% | 48,538.0 69.3% | 50,101.0 69.7% | 51,011.0 66.7% | 54,490.0 66.8% | 54,503.0 66.4% | 54,157.0 65.6% | 55,338.0 70.3% | 55,394.0 69.3% | 58,606.0 68.8% | 61,350.0 69.1% |
| Operating Expenses | 23,673.0 | 24,558.0 | 28,131.0 | 29,067.0 | 26,787.0 | 26,268.0 | 28,517.0 | 28,534.0 | 30,013.0 | 30,448.0 | 30,249.0 | 29,210.0 | 32,114.0 | 33,315.0 | 33,533.0 | 34,424.0 | 34,395.0 | 34,381.0 | 35,197.0 | 39,201.0 |
| Research & Development Expenses (R&D) | 6,462.0 | 7,125.0 | 7,680.0 | 7,577.0 | 6,986.0 | 6,844.0 | 7,548.0 | 7,665.0 | 8,183.0 | 8,494.0 | 9,046.0 | 9,143.0 | 10,594.0 | 10,775.0 | 11,355.0 | 12,340.0 | 14,277.0 | 14,135.0 | 15,085.0 | 17,232.0 |
| Selling, General & Administrative Expenses (SG&A) | 17,211.0 | 17,433.0 | 20,451.0 | 21,490.0 | 19,801.0 | 19,424.0 | 20,969.0 | 20,869.0 | 21,830.0 | 21,954.0 | 21,203.0 | 20,067.0 | 21,520.0 | 22,540.0 | 22,178.0 | 22,084.0 | 20,118.0 | 20,246.0 | 20,112.0 | 21,969.0 |
% margin | 12,831.0 25.4% | 13,709.0 25.7% | 15,213.0 24.9% | 16,169.0 25.4% | 16,663.0 26.9% | 16,527.0 26.8% | 16,153.0 24.8% | 17,032.0 25.3% | 18,957.0 26.6% | 21,137.0 28.4% | 18,289.0 26.1% | 20,891.0 29.1% | 18,897.0 24.7% | 21,175.0 26.0% | 20,970.0 25.6% | 19,733.0 23.9% | 20,943.0 26.6% | 21,013.0 26.3% | 23,409.0 27.5% | 22,149.0 24.9% |
| Interest Income | 0.0 | 0.0 | 452.0 | 361.0 | 90.0 | 107.0 | 91.0 | 64.0 | 74.0 | 67.0 | 128.0 | 368.0 | 385.0 | 611.0 | 357.0 | 111.0 | 53.0 | 490.0 | 1,261.0 | 1,332.0 |
| Interest Expense | 0.0 | 0.0 | 296.0 | 435.0 | 451.0 | 455.0 | 571.0 | 532.0 | 482.0 | 533.0 | 552.0 | 726.0 | 934.0 | 1,005.0 | 318.0 | 201.0 | 183.0 | 276.0 | 772.0 | 755.0 |
| Pre-tax Income | 13,116.0 | 14,587.0 | 13,283.0 | 16,929.0 | 15,755.0 | 16,947.0 | 12,361.0 | 13,775.0 | 15,471.0 | 20,563.0 | 19,196.0 | 19,803.0 | 17,673.0 | 17,999.0 | 17,328.0 | 16,497.0 | 19,178.0 | 19,359.0 | 15,062.0 | 16,687.0 |
% effective tax rate | 3,056.0 23.3% | 3,534.0 24.2% | 2,707.0 20.4% | 3,980.0 23.5% | 3,489.0 22.1% | 3,613.0 21.3% | 2,689.0 21.8% | 3,261.0 23.7% | 1,640.0 10.6% | 4,240.0 20.6% | 3,787.0 19.7% | 3,263.0 16.5% | 16,373.0 92.6% | 2,702.0 15.0% | 2,209.0 12.7% | 1,783.0 10.8% | 1,377.0 7.2% | 2,989.0 15.4% | 1,736.0 11.5% | 2,621.0 15.7% |
% margin | 10,060.0 19.9% | 11,053.0 20.7% | 10,576.0 17.3% | 12,949.0 20.3% | 12,266.0 19.8% | 13,334.0 21.7% | 9,672.0 14.9% | 10,853.0 16.1% | 13,831.0 19.4% | 16,323.0 22.0% | 15,409.0 22.0% | 16,540.0 23.0% | 1,300.0 1.7% | 15,297.0 18.8% | 15,119.0 18.4% | 14,714.0 17.8% | 20,878.0 26.5% | 17,941.0 22.4% | 35,153.0 41.3% | 14,066.0 15.8% |
| EPS | 3.38 | 3.76 | 3.67 | 4.67 | 4.45 | 4.86 | 3.54 | 3.91 | 4.90 | 5.86 | 5.57 | 6.08 | 0.48 | 5.75 | 5.74 | 5.59 | 7.93 | 6.83 | 13.88 | 5.84 |
| Diluted EPS | 3.35 | 3.73 | 3.63 | 4.57 | 4.40 | 4.78 | 3.49 | 3.86 | 4.81 | 5.70 | 5.48 | 5.93 | 0.47 | 5.61 | 5.63 | 5.51 | 7.81 | 6.73 | 13.72 | 5.79 |
% margin | 14,924.0 29.5% | 15,886.0 29.8% | 16,356.0 26.8% | 20,196.0 31.7% | 18,980.0 30.7% | 20,341.0 33.0% | 16,090.0 24.7% | 17,973.0 26.7% | 20,057.0 28.1% | 24,991.0 33.6% | 23,494.0 33.5% | 24,283.0 33.8% | 24,249.0 31.7% | 25,933.0 31.8% | 24,655.0 30.0% | 23,929.0 29.0% | 26,751.0 34.0% | 26,605.0 33.3% | 23,320.0 27.4% | 24,781.0 27.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Johnson & Johnson's Net Debt?
As of today, Johnson & Johnson's last 12-month Net Debt is $12.1B, based on the financial report for Dec 29, 2024 (Q4’2024).
2) What is Johnson & Johnson's Net Debt growth rate?
Over the last year, Johnson & Johnson's Net Debt growth was 89.1%. The average annual Net Debt growth rates for Johnson & Johnson have been 14.0% over the past three years, 7.6% over the past five years.
3) Is Johnson & Johnson's Net Debt growth rate Good?
Over the last year, Johnson & Johnson's Net Debt growth was 89.1%, which is higher than industry growth of 0.2%. It indicates that Johnson & Johnson's Net Debt growth is Bad.